GlassScriptPhysician profile
Angela Gonzalez
NPI 1700887346
$12,923.07
in general payments reported to CMS, 2019-2025
32 companies · $974 in 2025
The $974 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,680 · 2020: $2,483 · 2021: $2,330 · 2022: $830 · 2023: $1,657 · 2024: $969 · 2025: $974.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,599.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,136.36 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $1,615.49 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Amarin Pharma, INC. | $1,316.08 | 2019-2022 | |
| Amgen INC. | $1,283.73 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,253.27 | 2019-2025 | Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,135.70 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $866.38 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $493.30 | 2019-2021 | |
| Pfizer INC. | $436.96 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $391.37 | 2021-2024 | |
| Glaxosmithkline, LLC. | $286.15 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $285.59 | 2019-2021 | |
| Exact Sciences Corporation | $220.55 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Allergan, INC. | $171.85 | 2020 | |
| Abbvie INC. | $159.52 | 2021-2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $142.85 | 2020-2021 | |
| Insulet Corporation | $130.80 | 2025 | Omnipod |
| Sequel Med Tech, LLC | $119.20 | 2025 | Twiist |
| Abbott Laboratories | $98.09 | 2019-2023 | Mitraclip |
| Kowa Pharmaceuticals America, INC. | $69.04 | 2019-2021 | |
| Genentech USA, INC. | $52.46 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.80 | 2023-2025 | Xifaxan |
| Aimmune Therapeutics, INC. | $31.87 | 2025 | Zenpep |
| Ibsa Pharma INC. | $28.35 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.27 | 2019 | |
| Paratek Pharmaceuticals, INC. | $21.97 | 2021 | |
| Alnylam Pharmaceuticals INC. | $21.82 | 2020 | |
| Radius Health, INC. | $20.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.00 | 2021 | |
| Dompe US, INC. | $19.55 | 2022 | |
| Vbi Vaccine (Delaware) INC. | $18.49 | 2023 | Prehevbrio |
| Astellas Pharma US INC | $14.47 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.